ArticleGastroenterology and hepatology from bed to bench2025
Burden of pancreatic cancer in Iran: an analysis of Global Burden of Disease 2021.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term effects of human development on the global burden of gallbladder and biliary tract cancer: a longitudinal multilevel analysis, 1990-2021.Gastroenterology and hepatology from bed to bench · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess national and provincial trends in pancreatic cancer (PC) incidence, mortality, and mortality-to-incidence ratio (MIR) in Iran (1990-2021) using Global Burden of Disease (GBD) 2021 data. Background: PC is highly lethal, and recent burden estimates for Iran are limited. Methods: Age-standardized and age-specific incidence and mortality rates were obtained from the GBD Results Tool; MIR was calculated. Joinpoint regression was used to estimate average annual percentage change (AAPC) overall, by sex, and in adults aged ≥55 years. Results: From 1990 to 2021, age-standardized incidence and mortality increased by 80% (1.98 to 3.57 per 100,000) and 73% (2.12 to 3.65 per 100,000), respectively, while the MIR declined slightly (1.07 to 1.02) but remained above 1. Among adults ≥55 years, incidence and mortality nearly doubled (8.31 to 16.84 and 8.73 to 17.38 per 100,000, respectively), with minor MIR reductions (1.05 to 1.03). Joinpoint regression confirmed significant national increases in incidence (AAPC:1.88%) and mortality (AAPC:1.73%), alongside a modest decline in MIR (AAPC:-0.14%). Provincially, all regions exhibited rising age-standardized incidence and mortality, most steeply in Ilam and the lowest in Tehran. MIR generally declined, notably in Tehran, Lorestan, and Chaharmahal and Bakhtiari, though slight increases occurred in South/North Khorasan, Markazi, and Sistan and Baluchestan. Conclusion: PC burden in Iran has increased subs`tantially over the past three decades, especially among older adults and in certain provinces. Persistently high MIR indicates late diagnosis and poor survival, highlighting the need to strengthen cancer registries, improve early detection and diagnostic capacity, and address modifiable risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.